# Cobro Ventures

> Cobro Ventures is a VC fund backing Biotechnology and Health Care. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Arlington, United States
- Total investments: 17
- Last investment: Nov 2025
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cobro-ventures-inc
- Website: http://www.cobroventures.com

Cobro Ventures is a private investment firm focused on software and biotech. Our team has a 20 year track record of building successful businesses as founders, operators, and investors with both private and public exits. We provide resources, venture capital, and expertise to create significant value during critical phases of innovation.

## Contacts

5 contacts available for Cobro Ventures. Shizune tracks 2 team members at Cobro Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cobro-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 47% |
| Health Care | 5 | 29% |
| Medical | 4 | 24% |
| Therapeutics | 4 | 24% |
| Manufacturing | 2 | 12% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 35% |
| Series B | 5 | 29% |
| Seed | 4 | 24% |
| Series C | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 53% |
| Israel | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alain Cohen | Co-founder & CEO | 0 | https://shizune.co/investors/profile/alain-cohen-04b6 |
| Todd Kaloudis | Managing Director | 0 | https://shizune.co/investors/profile/todd-kaloudis-ba14 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AI Proteins | AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $42.5M | Series A | Nov 19, 2025 |  |
| Regenacy Pharmaceuticals | Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. | $9.3M | Series B | Aug 15, 2022 |  |
| NextRNA Therapeutics | NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. | $46.8M | Series A | Mar 01, 2022 |  |
| NextRNA Therapeutics | NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. | $46.8M | Series A | Mar 01, 2022 |  |
| AI Proteins | AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $18.2M | Seed | Jan 21, 2022 |  |
| Windgap Medical | WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack.The company was established in 2011 andis headquartered in Somerville, Massachusetts. | $39.2M | Series B | Sep 10, 2021 |  |
| TechsoMed | TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoringcapabilities, causing high failure rates.Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures. | $7M | Series B | Mar 03, 2021 |  |
| Mana Therapeutics | Educating Immune Cells, Eliminating Cancer. Our team of scientists, physicians, and advocates are passionate about one thing: harnessing our immune cells to combat cancer - conferring lifelong immunity to the disease. Meet the team charged with immune cell education and cancer elimination. | $35M | Series A | Jan 08, 2021 |  |
| C4 Therapeutics | C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $150M | Series B | Jun 16, 2020 |  |
| Regenacy Pharmaceuticals | Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. |  | Series A | Mar 25, 2020 |  |

10 of 17 investments shown.

## Co-investors
- [Rivas Capital](https://shizune.co/investors/profile/rivas-capital) — VC Fund, 6 deals together
- [Taiwania Capital Management Corporation](https://shizune.co/investors/profile/taiwania-capital) — VC Fund, 6 deals together
- [Axil Capital](https://shizune.co/investors/profile/axil-capital) — VC Fund, 4 deals together
- [Lightchain Capital](https://shizune.co/investors/profile/lightchain-capital) — VC Fund, 4 deals together
- [Yonjin Venture](https://shizune.co/investors/profile/yonjin-venture) — VC Fund, 4 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cobro Ventures invest in?

Cobro Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cobro Ventures?

Public channels for Cobro Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cobro Ventures?

The team at Cobro Ventures includes Alain Cohen (Co-founder & CEO) and Todd Kaloudis (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co